Bicycle Therapeutics plc
BCYC
$4.72
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 308.68% | 301.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 308.68% | 301.85% | |||
| Cost of Revenue | -18.89% | -20.30% | |||
| Gross Profit | 104.54% | 34.11% | |||
| SG&A Expenses | 9.06% | 11.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.41% | -13.67% | |||
| Operating Income | 68.71% | 24.31% | |||
| Income Before Tax | 67.93% | 25.62% | |||
| Income Tax Expenses | 517.07% | 188.74% | |||
| Earnings from Continuing Operations | 65.90% | 25.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 65.90% | 25.14% | |||
| EBIT | 68.71% | 24.31% | |||
| EBITDA | 69.95% | 24.86% | |||
| EPS Basic | 65.92% | 25.20% | |||
| Normalized Basic EPS | 75.07% | 25.68% | |||
| EPS Diluted | 65.92% | 25.20% | |||
| Normalized Diluted EPS | 75.07% | 25.68% | |||
| Average Basic Shares Outstanding | 0.09% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||